Church & Dwight CoCHD
Market Cap: $25.7B
About: Church & Dwight is the leading global producer of baking soda. Beyond baking soda, the products in its portfolio have vast category reach, including laundry products, cat litter, oral care, deodorant, and nasal care, all sold under the Arm & Hammer brand. Its mix also includes Batiste, OxiClean, Vitafusion, WaterPik, Hero, and TheraBreath, which together with Arm & Hammer constitute around 70% of its annual sales and profits. Even as it works to extend the reach of its products, Church & Dwight still derives more than 80% of its sales from its home market in the US.
Employees: 5,550
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
23% more call options, than puts
Call options by funds: $32.7M | Put options by funds: $26.6M
8% more funds holding in top 10
Funds holding in top 10: 13 [Q1] → 14 (+1) [Q2]
8% more first-time investments, than exits
New positions opened: 79 | Existing positions closed: 73
1% more funds holding
Funds holding: 992 [Q1] → 998 (+6) [Q2]
0% less capital invested
Capital invested by funds: $22.1B [Q1] → $22B (-$104M) [Q2]
11% less repeat investments, than reductions
Existing positions increased: 334 | Existing positions reduced: 376
78.36% less ownership
Funds ownership: 165.23% [Q1] → 86.87% (-78.36%) [Q2]
Research analyst outlook
11 Wall Street Analysts provided 1 year price targets over the past 3 months
11 analyst ratings
Barclays Lauren Lieberman 65% 1-year accuracy 55 / 85 met price target | 22%downside $82 | Underweight Maintained | 6 Aug 2024 |
Morgan Stanley Dara Mohsenian 85% 1-year accuracy 17 / 20 met price target | 5%upside $110 | Overweight Maintained | 5 Aug 2024 |
Evercore ISI Group Javier Escalante 33% 1-year accuracy 1 / 3 met price target | 4%downside $101 | In-Line Maintained | 5 Aug 2024 |
JP Morgan Andrea Teixeira 53% 1-year accuracy 32 / 60 met price target | 8%downside $97 | Underweight Maintained | 5 Aug 2024 |
Truist Securities Bill Chappell 64% 1-year accuracy 16 / 25 met price target | 5%upside $110 | Buy Maintained | 5 Aug 2024 |
Financial journalist opinion
Based on 3 articles about CHD published over the past 30 days